Application of PPA2 in the treatment and prognosis assessment of colorectal cancer

By studying the expression level of PPA2, it is determined as an important target for colorectal cancer, and technology for detection and treatment has been developed to solve the problems of high metastasis tendency and prognosis evaluation of colorectal cancer, significantly improving the treatment effect and patient survival rate.

CN118141902BActive Publication Date: 2024-11-12THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410394664.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-04-02
Publication Date
2024-11-12
Estimated Expiration
2044-04-02

AI Technical Summary

Technical Problem

The high metastasis tendency of colorectal cancer is difficult to reasonably evaluate in advance. The traditional efficacy is poor, and the lack of effective biomarkers and therapeutic targets affects the prognosis of patients.

Method used

By studying the expression levels of inorganic pyrophosphatase 2 (PPA2), it is determined as an important target for colorectal cancer, and agents and drugs for detecting PPA2 are developed to assist in diagnosis and prognostic evaluation, and to enhance PPA2 expression levels by increasing PPA2 Treatment effect.

Benefits of technology

The association between PPA2 and colorectal cancer metastasis was clarified, new therapeutic targets and prognostic evaluation methods were provided, which significantly improved the treatment effect and patient survival rate, and improved the prognosis of colorectal cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118141902B_ABST
    Figure CN118141902B_ABST
Patent Text Reader

Abstract

The present invention relates to the use of PPA2 in the preparation of colorectal cancer therapeutic drugs and / or prognosis judgment. The present invention discovered for the first time the biomarker PPA2 that is negatively correlated with colorectal cancer metastasis. The metastasis risk and prognosis of patients with colorectal cancer are determined by detecting the changes in PPA2 in tumor tissues of patients with colorectal cancer, and the metastasis risk of patients is reduced by activating PPA2, thereby improving the therapeutic effect. The present invention found that PPA2 is lowly expressed in tumor tissues and negatively correlated with poor prognosis of patients through clinical colorectal patient specimens and cohort follow-up data; at the same time, a series of in vitro functional experiments and animal models showed that PPA2 significantly inhibited colorectal cancer metastasis, and further found that this function is related to the negative regulation of HIF1α by PPA2, and activating the expression of PPA2 can enhance the efficacy and improve the prognosis of patients. The present invention provides new targets and methods for the diagnosis, prognosis evaluation and treatment of colorectal cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine and relates to the application of PPA2 in the treatment and prognosis evaluation of colorectal cancer. Background Art

[0002] Colorectal cancer is a common tumor worldwide, with new cases and cancer-related mortality ranking third in both men and women in the United States. However, colorectal cancer has an insidious onset, 25% of patients have distant metastasis when they seek medical treatment, and half of patients will eventually develop distant metastasis during treatment. Traditional treatments such as surgery, radiotherapy and chemotherapy are ineffective for metastatic colorectal cancer, with a 5-year survival rate of only 6%. Therefore, screening key functional targets for colorectal cancer metastasis and the discovery of effective biomarkers are of great significance for improving the prognosis of colorectal cancer patients.

[0003] Inorganic pyrophosphatase 2 (PPA2) belongs to the inorganic pyrophosphatase family and can catalyze the hydrolysis of pyrophosphate into inorganic phosphate, which is essential for phosphate metabolism in cells. Inorganic pyrophosphate is a byproduct of several enzymatic reactions in cells, including the synthesis of DNA and RNA, the activation of fatty acids and amino acids, etc. Pyrophosphate cannot be effectively exported through the cell membrane. It has been reported that inorganic pyrophosphatase activity is essential for the correct regulation of mitochondrial membrane potential and mitochondrial function, and PPA2 mutations may cause some serious cardiomyopathy. However, there is little research on the role of PPA2 in tumors. Summary of the invention

[0004] The purpose of the present invention is to address the problem that colorectal cancer has a high tendency to metastasize but is difficult to reasonably evaluate in advance in the prior art, thereby conducting in-depth research on the mechanism of colorectal cancer metastasis, clarifying that PPA2 is an important target related to colorectal cancer metastasis, and by detecting the PPA2 expression level in the patient's tumor tissue, the metastasis risk can be predicted, and by increasing the expression of PPA2, the therapeutic effect can be enhanced and the prognosis can be improved, providing a new strategy for colorectal cancer treatment and a scientific basis for prognosis evaluation.

[0005] In order to solve the above technical problems, the present invention is implemented through the following technical solutions.

[0006] The first aspect of the present invention provides the use of PPA2 in the preparation of a drug for treating colorectal cancer.

[0007] The second aspect of the present invention provides the use of PPA2 in the preparation of a product for auxiliary diagnosis and / or prognosis evaluation of colorectal cancer.

[0008] Preferably, the prognostic assessment indicator is selected from one or more of the risk of colorectal cancer cell metastasis and survival rate.

[0009] The third aspect of the present invention provides the use of a reagent for detecting the expression level of PPA2 in the preparation of a composition for auxiliary diagnosis and / or prognosis evaluation of colorectal cancer.

[0010] Preferably, the reagent for detecting the expression level of PPA2 includes primers for detecting the expression level of PPA2 gene and / or a reagent for detecting the expression level of PPA2 protein.

[0011] Preferably, the primers for detecting the expression level of the PPA2 gene are selected from the following primer pair: the upstream primer sequence of the primer pair is shown in SEQ ID NO: 1 (aagaagttcaaac cgggttacc), and the downstream primer sequence is shown in SEQ ID NO: 2 (gcaacggaaagggc tatcaga).

[0012] Preferably, the reagent for detecting the expression level of PPA2 protein is selected from PPA2 monoclonal antibody and / or PPA2 polyclonal antibody.

[0013] Preferably, the anti-PPA2 antibody for detecting the expression level of PPA2 protein can be selected from one or more of ab180859 (abcam), MA5-26973 (Thermo Fisher Scientific), and 16662-1-AP (proteintech).

[0014] Preferably, the prognostic assessment indicator is selected from one or more of the risk of colorectal cancer cell metastasis and survival rate.

[0015] The fourth aspect of the present invention provides a pharmaceutical composition for treating colorectal cancer, comprising one or more of PPA2 nucleotides and PPA2 proteins, and pharmaceutically acceptable excipients.

[0016] Preferably, the pharmaceutically acceptable excipient is selected from one or more of a filler, a disintegrant, a binder, a lubricant, a flavoring agent, a preservative, an antioxidant, and a colorant.

[0017] The fifth aspect of the present invention provides a kit for predicting the therapeutic efficacy and / or evaluating the prognosis of colorectal cancer, comprising a reagent for detecting the expression level of PPA2; and one or more of PCR enzyme, PCR buffer, dNTPs, and fluorescent substrate.

[0018] Preferably, the reagent for detecting the expression level of PPA2 includes primers for detecting the expression level of PPA2 gene and / or a reagent for detecting the expression level of PPA2 protein.

[0019] Preferably, the primers for detecting the expression level of the PPA2 gene are selected from the following primer pair: the upstream primer sequence of the primer pair is shown in SEQ ID NO: 1 (aagaagttcaaac cgggttacc), and the downstream primer sequence is shown in SEQ ID NO: 2 (gcaacggaaagggc tatcaga).

[0020] Preferably, the reagent for detecting the expression level of PPA2 protein is selected from PPA2 monoclonal antibody and / or PPA2 polyclonal antibody.

[0021] Preferably, the anti-PPA2 antibody for detecting the expression level of PPA2 protein can be selected from one or more of ab180859 (abcam), MA5-26973 (Thermo Fisher Scientific), and 16662-1-AP (proteintech).

[0022] Preferably, the fluorescent substrate is selected from Syber Green or a fluorescently labeled probe.

[0023] Preferably, the prognostic assessment indicator is selected from one or more of the risk of colorectal cancer cell metastasis and survival rate.

[0024] It should be understood that, in the context of the present invention, unless otherwise specified, the PPA2 includes components such as PPA2 nucleotides and PPA2 proteins encoded by PPA2 nucleotides. The PPA2 inhibitor refers to a substance that can specifically downregulate the expression level of PPA2 and / or the transcription level of its mature mRNA and / or the expression level or activity of PPA2 protein, for example, antisense oligonucleotides, siRNA, shRNA, sgRNA, antagomiRs, miRNA sponges, miRNA Erasers, TargetMasking and / or multi-target methods are used to downregulate the expression level and / or activity of PPA2, as long as the level and / or activity of PPA2 can be reduced. The primers and / or primer pairs refer to PCR primers used to synthesize the cDNA chain of the PPA2 gene in PCR, so as to detect the expression level of the PPA2 gene mRNA. In addition to the primers and / or primer pairs listed in the present invention, those skilled in the art are fully capable of designing corresponding primers and / or primer pairs according to the gene sequence of PPA2 using conventional methods and means in the field including but not limited to molecular biology, and screening the designed primers and / or primer pairs by conventional experimental means, as long as they can achieve specific detection of PPA2 expression levels; conventional reagents and methods in the field can also be used to detect PPA2 protein expression levels.

[0025] Compared with the prior art, the present invention has the following technical effects:

[0026] (1) The present invention found that PPA2 is a gene that is highly related to colorectal cancer metastasis through clinical colorectal cancer patient specimens and cohort follow-up data, and its expression level is significantly reduced in colorectal cancer tissues. The expression level of PPA2 is significantly negatively correlated with the poor prognosis of colorectal cancer patients, and can be used to assess the metastasis risk and prognosis of colorectal cancer patients to guide the formulation of treatment plans.

[0027] (2) The present invention has confirmed through a series of in vivo and in vitro experiments that PPA2 can inhibit the metastatic ability of colorectal cancer cells. By promoting the expression of PPA2, colorectal metastasis can be significantly inhibited, thereby improving the therapeutic effect. By revealing the correlation between PPA2 and colorectal cancer metastasis, the present invention has important practical significance for solving the difficult problems of clinical efficacy differences between individuals and blanks in prognostic evaluation, and better realizing precision treatment. It provides a new drug treatment target for humans to conquer colorectal cancer, thereby providing a new direction for subsequent drug development, clinical treatment, etc., and has extremely high social value and market application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 This is a schematic diagram of the results of immunohistochemical detection of PPA2 expression in colorectal cancer and adjacent tissues.

[0029] Figure 2 This is a schematic diagram of the results of WB detection of PPA2 expression in colorectal cancer and adjacent tissues.

[0030] Figure 3 This is a schematic diagram of the expression results of PPA2 in colorectal cancer and adjacent normal tissues in the TCGA and GEO colorectal cancer databases.

[0031] Figure 4 Schematic diagram of the results of immunohistochemical detection of PPA2 expression in tissues of patients with metastatic and non-metastatic colorectal cancer.

[0032] Figure 5 This is a schematic diagram showing the effect of PPA2 expression levels on prognosis in the early and late stages of the tumor in the TCGA colorectal cancer database.

[0033] Figure 6 This is a schematic diagram showing the effect of PPA2 expression in tumor tissue of colorectal cancer patients on their survival rate.

[0034] Figure 7 Schematic diagram of the detection results of the knockdown efficiency of PPA2 by shRNA and the overexpression efficiency of PPA2 by the overexpression vector.

[0035] Figure 8Schematic diagram of the effect of hypoxia treatment on Transwell migration of colorectal cancer stable cell lines.

[0036] Fig. 9 Schematic diagram of the effect of hypoxia treatment on scratch migration of colorectal cancer stable cell lines.

[0037] Fig.10 Schematic diagram of the results of WB detection of the effect of hypoxia treatment on the expression level of HIF1α in colorectal cancer stable cell lines.

[0038] Fig.11 Schematic diagram of the effect of PPA2 knockdown on the mouse spleen-injected colorectal cancer cell liver metastasis model. DETAILED DESCRIPTION

[0039] In order to make the purpose, technical scheme and effect of the present invention clearer and more specific, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0040] In the absence of special instructions, the cell lines listed in the context of the present invention, including HEK293T, DLD1, SW1116, etc., are cultured according to the prior art, and all cell lines are identified by short tandem repeat analysis of China Type Culture Collection (Wuhan), and the presence of mycoplasma contamination is verified using a PCR detection kit (Shanghai Biothrive Sci), and frozen in liquid nitrogen and used for subsequent experiments. The reagents used in the present invention are all commercially available. For the use of clinical specimens, informed consent forms were signed with patients, and the relevant procedures and methods meet the requirements of medical ethics and the quality management standards for drug clinical trials. The experimental methods used in the present invention, such as nucleic acid extraction, whole genome sequencing, primer design, immunohistochemistry, Western blot, cell experiments, etc., are all conventional methods and techniques in the art. Representative results are selected from the biological experiment repetitions and presented in the context drawings, and the data are displayed as mean±SD and mean±SEM as specified in the diagram. All in vitro experiments were repeated at least three times, and animal experiments were repeated twice. The data were analyzed using GraphPadPrism 8.0 software. Conventional medical statistical methods such as t-test, chi-square test, analysis of variance, etc. were used to compare the mean differences between two or more groups. *p < 0.05 was considered a significant difference.

[0041] Example 1

[0042] Biopsy samples of colorectal cancer patients from the First Affiliated Hospital of Sun Yat-sen University were selected. The inclusion criteria for patients were as follows: (1) aged 18 years or older (including 18 years old), both males and females; (2) patients with colorectal cancer confirmed by histology or pathology (stages I-IV); (3) paraffin sections prepared from fresh tumor biopsy tissues; (4) expected survival period greater than or equal to 3 months. First, immunohistochemistry was used to detect the expression level of PPA2 in the patient's tumor tissue and adjacent tissues. The specific steps are as follows:

[0043] (1) The biopsy sample tissue was embedded in paraffin for sealing. The paraffin specimen was stored at room temperature and the cut white slice was stored in a refrigerator at 4°C.

[0044] (2) During the experimental test, take out the paraffin sections and bake them in a 60°C oven for about 1 hour to allow the sections to adhere to the glass slide.

[0045] (3) Dewax the sections in two portions of xylene, each for 10 min.

[0046] (4) The sections were sequentially placed in gradient alcohol (100%, 100%, 90%, 80%, 70%) for hydration treatment, each for 5 min, and then washed three times with PBS, each for 3 min.

[0047] (5) Immerse the sections in EDTA antigen retrieval solution and heat them in a microwave oven at high temperature for 15 min for antigen retrieval. After heating, let the sections cool naturally to room temperature in the antigen retrieval solution and wash them three times with PBS, each time for 3 min.

[0048] (6) Place the slices in a light-proof humidified box, add a small amount of distilled water, cover the tissue with 3% hydrogen peroxide, and leave at room temperature for 20 minutes to completely remove endogenous peroxidase.

[0049] (7) Wash three times with PBS, 3 min each time. Add goat serum blocking solution to cover the tissue and block in a wet box at room temperature for 30 min to reduce nonspecific binding of the primary antibody.

[0050] (8) Shake off the blocking solution, add primary antibody to cover the tissue without washing, and place in a humidified box at 4°C for blocking overnight.

[0051] (9) The next day, the cells were placed at room temperature for 30 min, then washed with PBS for 3 min, and repeated three times.

[0052] (10) Add biotin-labeled secondary antibody, incubate at room temperature for 30 min, wash with PBS for 3 min, and repeat three times.

[0053] (11) DAB was added dropwise for color development, and after color development was complete, the reaction was terminated by placing the mixture in water.

[0054] (12) Add hematoxylin for 3 minutes for counterstaining, and place in water to terminate the staining; then add 1% hydrochloric acid alcohol for differentiation for 3 seconds, and rinse in running water for 30-45 minutes until the color of the section is stable for anti-blue treatment.

[0055] (13) Graded alcohol dehydration: Dehydrate the sections by immersing them in 70%, 80%, 90%, 100%, 100% alcohol, and xylene in sequence for 5 min each time, and then seal the sections.

[0056] Two independent researchers scored the clinical pathological immunohistochemical sections of the patients without knowing the patient information. The staining score was determined based on the staining intensity and the proportion of positive cells. The staining intensity was scored as follows: 0 (no staining), 1 (light), 2 (moderate), and 3 (strong). The proportion of PPA2-positive cells was scored as follows: 1 (<25%), 2 (25-50%), 3 (50-75%), and 4 (75-100%). The final score was obtained by multiplying the staining intensity and the proportion of positively stained cells. The test results are shown in Figure 1 The results showed that the expression level of PPA2 in colorectal cancer tissues was significantly lower than that in normal tissues (***p<0.001).

[0057] Subsequently, Western Blot was used to further verify the expression level of PPA2 in colorectal cancer tissues and adjacent tissues. The specific steps are as follows:

[0058] (1) Weigh 250 mg of colorectal cancer or adjacent tissue and place it in an EP tube. Wash twice with PBS, and then add 1× protease inhibitor and phosphatase inhibitor containing cell lysis buffer at 250 mg / mL. Homogenize with a glass homogenizer, homogenize at a low speed for 30 seconds each time, with an ice bath for 1 minute between each homogenization, until the tissue is completely lysed. Place on ice for 30 minutes to lyse, shaking every 10 minutes. After sufficient lysis, centrifuge at 4°C and 14,000 rpm for 15 minutes, and immediately transfer the supernatant to a new centrifuge tube.

[0059] (2) After protein quantification, add 5× protein loading buffer according to the sample volume, mix well, and incubate at 95°C in a water bath for 5 min.

[0060] (3) The protein sample obtained in step (2) was subjected to protein electrophoresis with the starting voltage set to 80 V. When the protein marker bands were clearly separated, the voltage was adjusted to 120 V.

[0061] (4) After protein electrophoresis, transfer can be performed. First, place the protein gel in the transfer solution for balance. Then add an appropriate amount of transfer solution into the container. Place the sponge, filter paper, PVD F membrane (activated with methanol), gel, filter paper, and sponge in order. Expel the gas and place the transfer tank in ice water. The transfer condition is 300 mA constant current for 1 hour.

[0062] (5) After the transfer is completed, place the membrane in 5% milk and block it on a shaker at room temperature for 1 hour.

[0063] (6) After blocking, wash the membrane once with 1× TBST buffer, cut the required bands, add the corresponding primary antibody, and place it on a shaker at 4°C overnight.

[0064] (7) Recover the primary antibody and wash the membrane three times with 1× TBST buffer, each time for 5 min.

[0065] (8) Incubate the secondary antibody at room temperature for 1 h, then wash the membrane three times with TBST buffer, 5 min each time.

[0066] (9) After washing the membrane, chemiluminescence can be performed. Prepare the ECL luminescence analyzer (A:B = 1:1) and use a Biorad chemiluminescence analyzer for luminescence development.

[0067] The experimental test results are as follows Figure 2 The results showed that the expression level of PPA2 in colorectal cancer tissues was significantly reduced, which was consistent with the results of the above tissue IHC analysis. By using the TC GA and GSEA databases, the analysis was performed by grouping cancer (T) and adjacent normal tissue (N). The results are shown in Figure 3 The results showed that the expression level of PPA2 in colorectal cancer tissues was significantly lower than that in adjacent normal tissues (***p<0.001), which was consistent with the analysis results of the above clinical samples.

[0068] Furthermore, samples of patients with metastatic and non-metastatic colorectal cancer were collected and analyzed by immunohistochemical staining according to the above method. Figure 4 The results showed that the expression level of PPA2 in the tumor tissue of the metastatic group was significantly lower than that of the non-metastatic group (***p < 0.001). The results were analyzed by using the TCGA colon (READ) and rectal cancer (COAD) database, as well as the early (Ⅰ / Ⅱ) and late (Ⅲ / Ⅳ) tumor groups. Figure 5 The results showed that PPA2 was negatively correlated with poor prognosis in the late stage of tumors, but had no significant correlation with the prognosis in the early stage of tumors. This suggests that PPA2 may affect the prognosis of advanced colorectal tumors by affecting their metastasis.

[0069] The above experiments have shown that PPA2 is lowly expressed in colorectal cancer tissues and highly expressed in normal tissues, and the expression level of PPA2 in colorectal cancer tissues is negatively correlated with tumor metastasis. In order to clarify the effect of PPA2 on the survival rate of colorectal cancer patients, the follow-up data of colorectal cancer patients after treatment in the First Affiliated Hospital of Sun Yat-sen University were analyzed and it was found that patients can benefit significantly from high expression of PPA2. The overall survival rate (OS) of patients with high expression of PPA2 in colorectal cancer tissues is significantly higher than that of patients with low expression of PPA2 (*p < 0.05) (see Figure 6 ).

[0070] Example 2

[0071] In the above examples, the effect of PPA2 expression level on the survival rate and treatment effect of colorectal cancer patients was clarified in clinical samples. In order to further study the effect of PPA2 on colorectal cancer, a series of in vitro experiments were conducted to further study it.

[0072] First, shRNA for reducing the expression level of PPA2 in cells and overexpression plasmids for increasing the expression level of PPA2 in cells were designed and their activities were verified. The specific steps are as follows:

[0073] (1) Design shRNAs knockdown sequences on the Sigma website, design primers based on the shRNA hairpin structure and synthesize primers, dilute the synthesized shRNAs primers with water to 100 μM, take 10 μL of the upstream and downstream primers respectively, mix them evenly, use a PCR instrument to gradually cool down from 100°C to room temperature, anneal to synthesize double strands, and transfect into the pLKO.1 lentiviral vector terminal; this embodiment uses two shRNAs as examples, namely shPPA2#1 (sequence as shown in SEQ ID NO: 3, gatcattagttgaatcggtat) and shPPA2#2 (sequence as shown in SEQ ID NO: 4, gcctcttctttaagaatgtaa); PPA2 (sequence as shown in SEQ ID NO: 5) was cloned into pCDH-Flag eukaryotic cells to construct an overexpression vector.

[0074] (2) pLKO.1 and pCDH-Flag were double-digested with EcoRI and AgeI endonucleases, respectively. After digestion, two single bands were obtained by running on gel. The larger band was cut out for gel recovery. The annealed double-stranded DNA was then connected to the vector after gel recovery.

[0075] (3) 293T cells in the logarithmic growth phase were seeded in a 10 cm culture dish at a seeding density of about 70%; 6000 ng of the target plasmid loaded with shPPA2#1, shPPA2#2 or PPA2, 4500 ng of PSPAX2 and 1500 ng of PMD2.G were transfected into the 293T cells and cultured for 48 h.

[0076] (4) After 48 hours, the culture medium was collected and the cell debris was filtered out with a 0.45 μm filter to obtain the virus solution, which was then aliquoted and stored at -80°C. One day before infection, the colorectal cancer cells (DLD1, SW1116) to be infected in the logarithmic growth phase were inoculated into a 6 cm culture dish, the original culture medium was discarded, 3 mL of the virus solution was added, and 3 uL of polybrene was added to promote virus infection. After 24 hours, the virus solution was discarded and fresh culture medium was replaced to continue the culture.

[0077] (5) 48 hours after infection, the culture medium is discarded and a culture medium containing an appropriate concentration of puromycin is added. At this point, cells that have successfully integrated the exogenous gene have puromycin resistance and can survive. After continuous screening for 7 to 10 days, a stable cell line can be obtained, and the PPA2 expression level can be detected by qPCR or WB to determine whether it is successfully knocked down or overexpressed.

[0078] The method for detecting the expression level of PPA2 in colorectal cancer cells by WB is the same as that in Example 1; the method for detecting the expression level of PPA2 in colorectal cancer cells by qPCR is as follows:

[0079] (1) After washing the cells with PBS, add 1 mL of Trizol to each well and place them horizontally at room temperature for 2 minutes to allow the lysis solution to evenly distribute on the cell surface and lyse the cells. Use a pipette to blow off the cells and then transfer the lysis solution to a 1 mL centrifuge tube without RNase.

[0080] (2) Incubate at room temperature for 5 min, centrifuge at 10,000 × g for 15 min at 4°C, aspirate the supernatant, add chloroform, shake vigorously, and incubate at room temperature for 3 min.

[0081] (3) Centrifuge at 10,000 × g for 15 min at 4°C. Carefully transfer the aqueous phase to a new centrifuge tube. Add an equal volume of isopropanol, mix well, and let stand at room temperature for 10 min.

[0082] (4) Centrifuge at 4°C and 10,000×g for 10 min, remove the supernatant, and wash with 1 mL of 75% ethanol (prepared with DEPC water).

[0083] (5) Centrifuge at 4°C and 7500×g for 5 min, discard the supernatant, open the lid and dry the precipitate, add 12 μL of DEPC water, incubate at 60°C for 10 min to dissolve the RNA and detect the concentration. Use HiScript II reverse transcriptase (Vazyme#R201-01) to reverse transcribe the total RNA into cDNA, and remove the genomic DNA at the same time. According to the measured RNA concentration, calculate the reaction system, as shown in Table 1 below.

[0084] Table 1 Reverse transcription reaction system

[0085]

[0086] (6) cDNA was diluted at a ratio of 1:5 as a template, and qPCR was performed using ChamQ SYBR qPCR Master Mix (Vazyme #Q712) from Novagen. The 96 / 384-well fluorescence quantitative PCR instrument was Biorad. The reaction system configuration (taking a total volume of 20 μL as an example) was as follows: 2× Taq Pro Universal SYBR qPCR Master Mix 10 μL, upstream primer 0.4 μL, downstream primer 0.4 μL, cDNA 2 μL, ddH2O 7.2 μL; the primer sequences and amplification procedures used are shown in Tables 2 and 3 below.

[0087] Table 2 Primer sequences

[0088]

[0089] Table 3 qPCR amplification program

[0090]

[0091] Test results such as Figure 7 The results showed that the two shRNAs designed according to the present invention can produce significant inhibitory activity on PPA2, reduce the expression levels of PPA2 protein and RNA in colorectal cancer cells, and the PPA2 overexpression vector can significantly increase the expression levels of PPA2 protein and RNA in colorectal cancer cells.

[0092] Subsequently, the Transwell assay and the scratch assay were used to study the effect of differences in PPA2 expression levels on the metastasis of colorectal cancer cells. The specific steps of the Transwell assay are as follows:

[0093] (1) After digesting the shNT, shPPA2, Vector, and PPA2 OE colorectal cancer cells constructed according to the above method, the cells were resuspended in serum-free culture medium, counted, and the cell density was adjusted to 1 million / mL.

[0094] (2) A Transwell culture chamber with a pore size of 8.0 μm was placed in a 24-well plate, 600 μL of culture medium containing 10% fetal bovine serum was added to the lower layer of the chamber, and 100 μL of the serum-free cell suspension counted in step (1) was added to the inner chamber. One group was cultured under conventional conditions (37 degrees 5% CO2 incubator), and the other group was cultured in an anaerobic incubator for 48 hours.

[0095] (3) The Transwell chamber was removed and fixed with 4% paraformaldehyde for 15 minutes and stained with 0.1% crystal violet for 20 minutes. The cells on the upper layer of the microporous membrane were carefully wiped off with a cotton swab. After washing twice with PBS, the cells on the lower layer were photographed and counted under a microscope.

[0096] Test results such as Figure 8 The results showed that shPPA2 slightly promoted tumor cell migration under normal oxygen conditions, and this effect was more significant under hypoxia. Conversely, PPA 2OE could significantly inhibit tumor cell migration under hypoxia.

[0097] The specific steps of the scratch test are as follows:

[0098] (1) Use a marker pen and a ruler to evenly draw horizontal lines on the back of the 6-well plate, approximately every 0.5-1 cm, across the wells. Make at least 5 lines across each well.

[0099] (2) Add approximately 2 million cells to the wells. The specific number will vary depending on the cell type, but the amount should be sufficient to cover the bottom of the wells overnight.

[0100] (3) The next day, use the tip of the gun to measure against the ruler and try to make it as close as possible to the horizontal scratch mark on the back. The tip of the gun should be vertical and not tilted.

[0101] (4) Wash the cells three times with PBS, remove the scratched cells, and add serum-free culture medium.

[0102] (5) One group was cultured under normal conditions (37°C, 5% CO2 incubator), and the other group was cultured in an anaerobic incubator. Samples were taken at 0, 12, and 24 hours, and observed and photographed under a microscope.

[0103] Test results such as Fig. 9 The results showed that shPPA2 could slightly promote tumor cell migration under normal oxygen conditions, and this effect was more significant under hypoxia (***p < 0.001), while PPA2 OE could more significantly inhibit tumor cell migration under hypoxia (***p < 0.001).

[0104] HIF1α is a key molecule in the cell's response to hypoxia. It is continuously ubiquitinated and degraded under normoxic conditions, but remains stable under hypoxic conditions and transcriptionally activates many downstream target genes, playing an important role in promoting angiogenesis, cell proliferation, metastasis, metabolic reprogramming, etc. It has been reported that HIF1α is abnormally upregulated in a variety of tumors and is closely related to various malignant behaviors of tumor cells. Therefore, according to the WB detection method described in Example 1, the expression level of HIF1α in shNT, shPPA2 (shPPA2#1), Vector, and PPA2 OE colorectal cancer cells under normoxic and hypoxic conditions was detected. The results are as follows Fig.10 The results showed that under hypoxic conditions, the HIF1α expression level of shPPA2 cells was significantly increased compared with shNT cells, while the HIF1α expression level of PPA2 OE cells was significantly decreased compared with Vector cells.

[0105] Further, the effect of PPA2 on tumor metastasis in vivo was studied, and the specific steps were as follows:

[0106] (1) Six-week-old female C57BL / 6J mice were housed in an SPF environment.

[0107] (2) After digestion and resuspending in PBS, count the above shNT and shPPA2 (shPPA2#1, sh PPA2#2) colorectal cancer cells and adjust the concentration to 25 million / mL. Make a 1 cm transverse incision on the skin about 1-2 cm below the left ribs, and cut the skin layer and muscle layer.

[0108] (3) Clamp the pancreatic tail that is attached to the spleen and pull it out of the body together with the spleen. Use the insulin needle to absorb the mixed cell suspension and slowly inject 100 μL. The color of the spleen will become lighter. Slowly withdraw the needle and gently push the spleen and fat back into the abdominal cavity. Suture the muscle layer and skin layer separately. About two months later, anesthetize the mice, kill them, dissect them, and take out the liver for observation and testing.

[0109] Test results such as Fig.11 The results showed that shPPA2 could significantly promote the liver metastasis of colorectal cancer cells.

[0110] It can be clearly seen from the above that PPA2 is a gene related to colorectal cancer metastasis. The lower expression level of PPA 2 has a significant positive correlation with poor prognosis, which can be used to predict the risk of colorectal cancer metastasis and prognosis, and provide a reference for patients to specify treatment plans. At the same time, promoting PPA2 expression has the important function of inhibiting colorectal cancer metastasis. Correspondingly, the metastasis risk of patients can be reduced and the prognosis of patients can be improved by increasing the expression level of PPA2 in the body; and it is further found that this function is related to the negative regulation of HIF1a by PPA2, and the present invention also provides a new idea for the study of targeted HIF1a treatment. The present invention reveals the correlation between the PPA2 gene and colorectal cancer metastasis, which is of great significance for solving the problem of gaps in metastasis risk assessment between individuals, and helps to better achieve precision treatment. It provides a new drug treatment target for humans to conquer colorectal cancer, thereby providing a new direction for subsequent drug development, clinical treatment, etc., and has extremely high social value and market application prospects.

[0111] The above specific implementation method part specifically introduces the analytical method involved in the present invention. It should be noted that the above introduction is only to help those skilled in the art better understand the method and ideas of the present invention, rather than limiting the relevant content. Without departing from the principle of the present invention, those skilled in the art may also make appropriate adjustments or modifications to the present invention, and the above adjustments and modifications shall also fall within the scope of protection of the present invention.

Claims

1. Use of PPA2 gene and / or protein in the preparation of drugs for treating colorectal cancer.

2. Use of the PPA2 gene and / or protein in the preparation of products for auxiliary diagnosis and / or prognosis assessment of colorectal cancer.

3. The use according to claim 2, It is characterized in that The prognostic evaluation index is selected from one or more of the colorectal cancer cell metastasis risk and survival rate.

4. Use of a reagent for detecting PPA2 expression level in the preparation of a composition for auxiliary diagnosis and / or prognosis evaluation of colorectal cancer, wherein the reagent for detecting PPA2 expression level comprises primers for detecting PPA2 gene expression level and / or a reagent for detecting PPA2 protein expression level.

5. The use according to claim 4, It is characterized in that The primers for detecting the expression level of the PPA2 gene are selected from the following primer pair: the upstream primer sequence of the primer pair is shown as SEQ ID NO: 1, and the downstream primer sequence is shown as SEQ ID NO:

2.

6. The use according to claim 4, It is characterized in that The reagent for detecting the expression level of PPA2 protein is selected from PPA2 monoclonal antibody and / or PPA2 polyclonal antibody.

7. The use according to claim 4, It is characterized in that The prognostic evaluation index is selected from one or more of the colorectal cancer cell metastasis risk and survival rate.